Polyphenols and Microvascular Function in Humans: A Systematic Review. by Woodward, KA et al.
 Woodward, KA, Draijer, R, Thijssen, DHJ and Low, DA
 Polyphenols and Microvascular Function in Humans: A Systematic Review.
http://researchonline.ljmu.ac.uk/7547/
Article
LJMU has developed LJMU Research Online for users to access the research output of the 
University more effectively. Copyright © and Moral Rights for the papers on this site are retained by 
the individual authors and/or other copyright owners. Users may download and/or print one copy of 
any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. 
You may not engage in further distribution of the material or use it for any profit-making activities or 
any commercial gain.
The version presented here may differ from the published version or from the version of the record. 
Please see the repository URL above for details on accessing the published version and note that 
access may require a subscription. 
For more information please contact researchonline@ljmu.ac.uk
http://researchonline.ljmu.ac.uk/
Citation (please note it is advisable to refer to the publisher’s version if you 
intend to cite from this work) 
Woodward, KA, Draijer, R, Thijssen, DHJ and Low, DA (2017) Polyphenols 
and Microvascular Function in Humans: A Systematic Review. Current 
Pharmaceutical Design, 23. ISSN 1381-6128 
LJMU Research Online
1 
 
Polyphenols and Microvascular Function  
in Humans: A Systematic Review 
 
Kirsty A. Woodward,a Richard Draijer,b Dick H. J. Thijssen,a,c David A. Lowa  
 
 
a
 Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, 
Liverpool, UK 
b
 Unilever Research & Development, Olivier van Noortlaan 120, 3133 AT, Vlaardingen, The 
Netherlands 
c
 Radboud Institute for Health Sciences, Department of Physiology, Radboud University 
Medical Center, Nijmegen, The Netherlands  
 
 Author for correspondence: Dr David A. Low, Research Institute for Sport and Exercise 
Sciences, Liverpool John Moores University, Byrom Street, L3 3AF, Liverpool,  
United Kingdom. 
Email: d.a.low@ljmu.ac.uk 
Tel.: +44 (0)151 904 6244 Fax: +44 (0)151 904 6284 
 
Running title: Polyphenols and Microvascular Function 
Number of figures: 4 
Number of tables: 10  
Keywords: microcirculation, cardiovascular disease, flavonoids 
  
2 
 
ABSTRACT (graphical abstract included)  
Background: Polyphenol-rich dietary sources are acknowledged to have potential 
cardiovascular health benefits, particularly in reducing cardiovascular disease risk. Methods: 
This systematic review sought to determine the effect of polyphenol-rich foods and beverages 
upon microvascular function, which is of considerable importance in its contribution towards 
the pathophysiology of microvascular-related complications but also in the future development 
of (macro-vessel) cardiovascular disease. Results: Overall, consumption of polyphenol-rich 
foods and beverages demonstrate improved microvascular function, although this is 
dependent upon the polyphenol source, the dose of the product, the duration of consumption 
and the population group studied. Most subgroups reviewed suggest an overall beneficial 
effect on microvascular function, particularly grape-derived products, cocoa, tea, pine bark 
and Rutaceae aurantiae. Other groups remain equivocal and require further study due to the 
limited research performed to date. Conclusion: Polyphenols are abundant in the human diet 
and this systematic review demonstrates that they are an inexpensive, non-pharmacological 
approach for improving cardiovascular health in currently healthy individuals and in 
populations with microvascular dysfunction. 
 
INTRODUCTION 
The phrase ‘you are what you eat’ refers to the notion that you can contribute to a healthy 
body and mind by eating the right foods, such as fruits and vegetables, and consuming others 
in moderation which are, among others, rich in empty calories, saturated fat and salt. How 
food impacts upon health remains, however, largely obscure. We have reviewed, therefore, 
the evidence for one specific dietary molecular subgroup, polyphenols, found in many fruits 
and vegetables and their effect upon microvascular function contributing to cardiovascular 
health and beyond.  
 
Structure and Function of the Cardiovascular System  
The cardiovascular system is a complex, interrelated organ system that is composed of the 
heart, vasculature and blood which together serve three primary functions: transportation, 
homeostasis and protection. The cardiovascular system forms an efficient delivery network for 
cellular nutrition and removal of metabolic waste products, gaseous exchange and hormonal 
transport, in addition to being a key regulator of homeostasis for body temperature, pH 
balance, hydration and blood pressure [1]. In order to achieve these vital functions, however, 
the cardiovascular system must closely interact with other major systems, particularly the 
respiratory, neural, endocrine, digestive, skeletal, urinary and integumentary systems. In this 
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regard, the vascular tree, particularly the microvasculature, is integral in providing an extensive 
transport network of vessels to serve each of these systems as a site to facilitate exchange of 
macromolecules and fluids, in addition to responding to various mechanical forces and 
chemical signals concerned with homeostasis and protection [2].  
 
Microvasculature  
The microvasculature encompasses the smallest resistance vessels (<150µm in diameter) 
embedded within all human tissues and organs, consisting of terminal arterioles, capillaries 
and venules [3, 4]. Pre-capillary resistance vessels regulate local blood perfusion according 
to local metabolic demand, via neural, myogenic, metabolic and flow-induced (chemically-
mediated) mechanisms. Vasodilators associated with neural pathways are primarily 
acetylcholine (ACh), calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide 
(VIP) and substance P, with vasoconstriction achieved following sympathetic activation [4]. 
The vascular smooth muscle cells within the vessel wall (tunica media) closely interact with 
the endothelial monolayer which is innervated by autonomic nerves and local chemical 
mediators such as nitric oxide (NO).  
 
Optimal microvascular function is essential for organ systems to function effectively, from the 
brain, eyes, kidneys, heart, muscle, adipose tissue to the skin. The cerebral microcirculation 
serves a pivotal role in homeostatic control to enable adequate central nervous system 
function. Precise regulation is required due to the brain’s high metabolic rate and its limited 
capacity for energy storage, which is achieved through a combination of complex endothelial, 
myogenic, metabolic and neural regulatory mechanisms [5, 6]. Blood flow regulation in the 
human eye is complex and serves to maintain adequate eye health. Two vascular systems 
supply the eye; the retinal vessels supply the retina and prelaminar portion of the optic nerve 
and the ciliary vessels supply the rest of the eye [7]. Ocular blood flow is governed by local 
vascular control mechanisms, in addition to neural, systemic, endocrine and paracrine factors. 
The kidney is another highly complex organ that requires a well-regulated oxygen supply to 
meet a high energy demand. However, the kidney is vulnerable to hypoxaemic injury so the 
microvasculature is critical in ensuring a well regulated and maintained oxygen supply [8, 9]. 
The coronary microcirculation is responsible for ensuring that the cardiac muscle receives 
adequate oxygen and nutrition to perform its function as the engine of the human body [10]. 
Furthermore, the microvasculature needs to respond efficiently to local metabolic demand, 
particularly during times of cardiac stress such as physical exertion. These local metabolic 
demands are also true of the skeletal muscle microvasculature. Adequate perfusion is required 
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for tissue metabolism and maintenance of muscle mass [11, 12]. Adipose tissue requires 
adequate blood flow to and from adipocytes for lipid deposition and its utilisation as an energy 
source [13]. The microvasculature in the skin has been studied extensively, due to its relative 
ease of accessibility. It is a highly specialised vascular network that is organised into two 
plexuses in the dermis; superficial and deep layers which run parallel to the surface of the 
skin, with the majority of vessels located in the superficial plexus [14]. Skin blood flow is 
primarily concerned with temperature regulation and to a lesser extent, fulfilling nutritive 
demands. Non-glabrous skin of the limbs, head and trunk is largely governed by dual 
sympathetic neural control through noradrenergic vasoconstrictor and cholinergic vasodilator 
mechanisms [14, 15], in addition to local factors such as endothelial release of NO.  
 
Microvascular Dysfunction  
The microcirculation continues to receive widespread attention for its contribution towards 
overt cardiovascular disease and type 2 diabetes [16-19]. Considered a transitional stage 
between diet-induced obesity and insulin resistance [20, 21], microvascular dysfunction is 
characterised by structural and functional changes to the microvasculature that largely arise 
from impaired endothelial function. A healthy endothelium is essential for maintaining overall 
vascular health. As a major regulator of vascular homeostasis, the endothelial monolayer is 
crucial in maintaining the balance between vasodilation and vasoconstriction [22]. 
Endothelium-derived chemical mediators are central to this regulated equilibrium, with any 
disturbance leading to endothelial dysfunction and the associated pathological processes of 
cardiovascular and metabolic diseases [22-24]. Microvascular dysfunction often precedes 
microvascular complications and (macro) vascular dysfunction in larger vessels that 
subsequently leads to pathological interactions and the development of both small and large 
vessel disease [25], such as atherosclerosis and other plaque-related problems including 
stenosis and ischaemic vascular disease.  
 
Many diseases arising from microvascular dysfunction share similar pathological pathways 
relating to inflammatory processes, endothelial dysfunction and altered glucose metabolism. 
Therefore, dysfunction is often present in multiple organs concurrently. Without intending to 
be fully comprehensive, the following examples illustrate the importance of a functional 
microcirculation. Microvascular degeneration arising from advancing age and other 
cardiovascular risk factors is associated with cerebrovascular disease, such as stroke arising 
from microbleeds [26] and Alzheimer’s disease [27]. Furthermore, cerebral hypoperfusion 
leads to increased systemic blood pressure as a compensatory mechanism to ensure that the 
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brain tissue receives enough oxygen and nutrients in order to function adequately [28]. This 
compensation can lead to the development of systemic cardiovascular disease, such as 
essential hypertension. Impaired renal microcirculation leading to hypoxaemia is associated 
with acute and chronic kidney disease [9, 29]. Altered function in the retinal microvessels can 
lead to the development of retinopathy, with the retinal vessels also providing a biological 
model to detect the early manifestation of hypertension [30]. Coronary microvascular 
dysfunction is associated with changes such as reduced coronary flow reserve that is present 
in diseases including arterial hypertension, hypertrophic cardiomyopathy and diabetes mellitus 
[31]. The skeletal muscle is critical in regulating nutrient metabolism, and microvascular 
dysfunction leads to changes in glucose metabolism that arise from insulin resistant pathways 
[32]. Such changes in the microvasculature in various organs are closely related to the 
mechanisms underlying many cardiometabolic diseases.  
 
Microvascular Function – Measurement Techniques  
Several methods of measuring microvascular function (Figure 1) have been developed due to 
continued clinical interest in the role of microvessels, particularly since microvascular beds are 
thought to exhibit detectable changes in endothelial (dys)function earlier than macrovessels 
[3, 22, 24, 33] and can provide an insight into the mechanisms underlying these disease 
states. The cutaneous microcirculation is an easily accessible vascular bed that may be used 
as a surrogate for generalised vascular function [34]. Various approaches have been used to 
measure skin blood flow (SkBF), such as, venous occlusion plethysmography (VOP), laser 
Doppler flowmetry (LDF), videomicroscopy, laser Doppler perfusion imaging (LDPI) and laser 
speckle contrast imaging (LSCI) [14, 35], and typically involve measures being taken from 
limited regions due to the heterogeneity of the microvascular anatomy and underlying control 
mechanisms [14]. The most commonly used techniques for assessing microvascular function 
are briefly described below.  
 
Venous occlusion plethysmography (VOP). This technique has been used extensively to 
determine whole limb (e.g., muscle and skin) blood flow based upon the rationale that the 
(subdiastolic) occlusion of venous outflow from an extremity (forearm/leg) induces a change 
in its volume that corresponds proportionally with continued arterial inflow [36]. Blood flow is 
calculated according to limb volume change by displacement or circumference change [14].  
Laser Doppler flowmetry (LDF). Routinely used to study microvascular function, LDF is 
sensitive in detecting changes in skin perfusion over a period of time and in response to 
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transient pharmacological and non-pharmacological stimuli, including local thermal 
hyperaemia (LTH), post-occlusive reactive hyperaemia (PORH) and iontophoresis of 
vasodilators [37, 38]. LDF is based upon the reflection, scatter and Doppler shift of laser 
emitted photons in detecting moving red blood cells [37]. The magnitude and frequency of the 
Doppler shifted photons and the change in wavelength is related to the concentration and 
velocity of blood cells [14, 37]. LDF is superior to other measures of SkBF due to its continuous 
signal, excellent temporal resolution and high spatial resolution [14]. Depending on the depth 
utilized, LDF can be applied to many tissues including the skin, intestine, bone and muscle.  
 
Laser Doppler perfusion imaging (LDPI). This technique is based on light scattering in tissue 
as in LDF, but rather than being a single-point measurement covering ~1 mm2, it combines 
several single measurements taken over a tissue surface to produce a single image of overall 
microcirculation covering up to 2500 mm2 [35, 39]. A movable scanning mirror directs the laser 
beam to the measurement sites, but this is a time-consuming process that requires processing 
of vast amounts of raw data; typically, 4,096 measurement sites recorded over a 4-min period 
are required for a single perfusion image [35, 40]. LDPI is most frequently used in evaluating 
cutaneous function, largely to assess various wounds and ulcers, rather than as an index of 
microvascular function per se. The poor temporal resolution makes this technique less able to 
assess changes in skin perfusion that occur across shorter time frames, such as during (local) 
heating, exercise or drug infusions. 
 
Laser speckle contrast imaging (LSCI). Laser speckle is generated when tissue is illuminated 
by laser light. This speckle pattern changes when blood cells move within the region of interest 
and creates blurring of the captured image; higher levels of movement (fast flow) produce a 
more blurred image that reduces the contrast in the region, with lower levels of movement (low 
flow) corresponding with an increase in contrast [35, 41]. The advantage of LSCI over LDPI is 
that LSCI is a near-instant measure of the whole tissue, rather than scanning multiple times. 
Video frame rate blood flow images (up to 25 per second) enable immediate tracking of fast 
transient changes in blood flow over a surface area from 5x7mm to 15x20cm, to a depth of 
approximately 150-300 micron [35, 41]. LSCI is a usual method for evaluating cutaneous 
microcirculation and has also been used to assess intraoperative cerebral microcirculation, as 
well as retinal perfusion.  
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Videomicroscopy. Direct visualisation of the microcirculation is achieved using orthogonal 
polarisation spectral (OPS) imaging and, more recently, sidestream darkfield (SDF) imaging 
[35]. These techniques illuminate the tissue via polarised light from an external or integrated 
light source, respectively, and allow the measurement of vessel diameter, vessel density and 
red blood cell velocity. Videomicroscopy has been used to study microvascular blood flow in 
the sublingual mucosa, in addition to the gingiva, skin, liver and conjunctiva [35, 42]. 
 
Capillary microscopy. This technique is a simple, non-invasive method of assessing 
microvascular function of the nailfold capillaries, including their morphology, density and blood 
velocity, and is useful in detecting microangiopathies such as Raynaud’s phenomenon and 
hypertension [43, 44].  
 
Additional methodologies can also be used to investigate microvascular function in other 
organs. Assessment of cerebral perfusion is difficult due to the natural skull barrier. Several 
non-invasive techniques have been developed including single photon emission computing 
tomography (SPECT), positron emission tomography (PET), dynamic perfusion computed 
tomography (PCT) and arterial spin-labelling (ASL) functional magnetic resonance imaging 
(fMRI) that can examine regional micro- through to macrovascular cerebral perfusion. Renal 
perfusion may be assessed via blood oxygen level-dependent (BOLD) MRI which gives an 
index of tissue oxygenation (pO2) [45], with alternative methods including ASL fMRI and PET 
scans [46]. The retinal microvasculature is assessed through advanced imaging techniques 
focusing on static structural features and dynamic retinal analysis related to functional 
measures (e.g. flow), which have been reviewed comprehensively by Liew and colleagues 
(2008). Coronary microvascular function is assessed via invasive methods such as 
intracoronary Doppler and non-invasive methods such as transthoracic Doppler 
echocardiography (TTDE) which allows calculation of the coronary flow reserve and can be 
used as an index of coronary microvascular dysfunction [31, 48].  
 
Modifiable Risk Factors  
It is important to recognise pre-disease as a window of opportunity to improve endothelial and 
overall microvascular function to prevent/limit progression towards clinical pathology. 
Therapeutic strategies include a variety of drug therapies that target improved microvascular 
function through structural modifications. Current non-pharmacological strategies for 
preventing the progression of microvascular dysfunction in pre-diseased states are primarily 
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focused on controlling modifiable risk factors, particularly related to lifestyle modification. 
Physical inactivity and obesity are considered two of the most important risk factors for the 
development of cardiometabolic disorders. Sedentariness and excessive caloric intake 
through altered dietary structure promote a positive energy balance that increase central 
adiposity and body weight [49]. Dietary components also have profound effects upon 
microvascular health. Salt intake has been linked to hypertension arising via dysfunction due 
to microvascular rarefaction [50]. Modest reductions in salt intake have demonstrated both 
functional and structural improvements to capillary rarefaction [51][51, 52]. Excessive dietary 
protein is linked to renal damage through hyperfiltration [53], although the current scientific 
evidence remains equivocal [54]. However, other dietary components are suggested to exert 
a positive influence upon cardiovascular health, such as fruits and vegetables, spices, omega-
3-fatty acids and low-fat dairy products [55]. As the deleterious effects of sedentary lifestyles 
have become more apparent and the beneficial effects of certain dietary components receive 
wider scientific recognition, dietary interventions have received greater attention as 
inexpensive tools to combat the ever-increasing global burden of cardiovascular disease.   
 
 
Dietary Intervention: The Role of Polyphenols  
The Mediterranean diet is widely reputed to exert a protective effect upon cardiometabolic 
health, largely achieved via mechanisms related to its richness in plant-derived products, such 
as olive oil, fruits and vegetables, which contain bioactive compounds known as polyphenols 
[56]. These naturally occurring compounds are the most abundant antioxidant in the human 
diet; to date, in excess of 8,000 polyphenolic compounds have been identified [57]. 
Polyphenols can be broadly categorised into four subclasses (Figure 2) according to their 
phenolic ring structure and ring-binding elements: flavonoids, phenolic acids, lignans and 
stilbenes [57, 58].  
 
Flavonoids account for the greatest proportion of polyphenols (60%) and are characterised by 
two or more aromatic rings bound together by a 3-carbon bridge forming an oxygenated 
heterocycle, with the degree of oxidation generating further subclasses, in ascending order of 
oxidation: flavanols (often called catechins), flavanones, flavones, isoflavones, flavonols and 
anthocyanins (Figure 2) [59, 60]. Hydroxylation and conjugation patterns of the aromatic rings 
further characterises the individual flavonoids and isoflavones within these subclasses [60]. 
Phenolic acids are the second most abundant polyphenol subclass, accounting for 30% of 
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dietary polyphenols [59]. These can be categorised as hydroxybenzoic acids, as found in tea, 
and hydroxycinnamic acids which are found in coffee, cinnamon and fruits such as blueberries, 
apples and plums [57, 61]. Lignans are diphenolic compounds formed of 2 phenylpropane 
units and are found in fruits, legumes, cereals and grains [61]. Several lignans are regarded 
as phytoestrogens, such as secoisolariciresinol [57] which is found in linseed (flax), the richest 
sources of lignans. Stilbenes are the final of the four polyphenol subclasses and are 
characterised by two phenyl moieties connected by a two-carbon methylene bridge. Low 
quantities of stilbenes occur in the human diet, with resveratrol and pterostilbene considered 
the main ones. Resveratrol is the most widely known of the two and is found in grapes and its 
derivative red wine, as well as blueberries, cranberries and peanuts. Pterostilbene is also 
found in grapes and blueberries, and is suggested to have superior bioavailability compared 
to resveratrol, in addition to neuroprotective properties in age-related diseases [62].  
 
Epidemiological research has explored the effects of a variety of polyphenol-rich foods upon 
cardiovascular health, with beneficial effects observed for glycaemic control [63, 64] and 
macrovessel endothelial (dys)function [65]. Furthermore, a negative correlation has been 
identified between the consumption of polyphenol-rich dietary products and cardiovascular 
disease incidence [66-68]. As the microcirculation represents an important vascular bed in the 
pathogenesis of many cardiometabolic diseases, it is important to review the current literature 
to determine the effect of polyphenol-rich foods and beverages upon microvascular function 
in several of organ systems. Therefore, in this chapter, we will perform a systematic review 
pertaining to the literature that examined the impact of polyphenols on microvascular function. 
 
METHODS  
Search strategy  
The PubMed database was searched for studies in the English language between 1945 and 
June 2016 involving human subjects. A combination of medical subject heading (MeSH) 
search terms were used (microcirc* OR microvasc* OR microvessels OR capillar* OR 
arterioles OR venules OR iontophoresis OR blood flow OR perfusion OR vasodila* OR laser 
Doppler OR videocapillaroscopy OR laser speckle OR NIRS OR plethysmography) AND 
(polyphenol* OR flavonoid* OR catechin* OR flavanol* OR flavan-3-ols OR flavonol* OR 
isoflavone* OR flavanone* OR flavone* OR anthocyanidin* OR proanthocyanidin* OR 
epicatechin OR EGCG OR quercetin OR kaempferol OR myricetin OR resveratrol) AND 
(human OR subjects OR volunteers OR patients OR males OR females).  
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Inclusion of studies  
A total of 2567 studies were identified through the PubMed database search. Three 
independent investigators (K.W., R.D. and D.L.) reviewed the studies using a systematic 
hierarchy of exclusion criteria: in vitro, review article, not polyphenols, not microcirculation, not 
human and ex vivo (see Figure 3). A total of 2399 abstracts were excluded, with 168 full-text 
articles going forward to the next stage. Studies were excluded according to the same 
exclusion criteria as for the abstracts, in addition to the following: if the contribution of 
microcirculation to the vascular measurement could not be determined (e.g. pulse form 
analysis or fMRI), no full paper was available, duplicate paper, not oral administration of 
polyphenols and data was unavailable for inclusion (requested from the authors but no 
response received). A total of 55 studies fulfilled all review criteria and the extracted data are 
shown in Tables 1 to 9, in which the tested polyphenols are aggregated per dietary source or 
listed as pure polyphenols.  
 
RESULTS AND DISCUSSION  
For many years polyphenol-rich dietary sources have been acknowledged to have potential 
cardiovascular health benefits, particularly in reducing cardiovascular disease risk [69-72]. 
Also, in the 1950s citrus polyphenols, at that time called ‘vitamin P’, were shown to affect 
capillary fragility in rabbit ears [73]. Nevertheless, the research on polyphenols improving 
microvascular function in different vascular beds and linking that to a (cardiovascular) benefit 
is still in his infancy, reflected by the fact that 50% of the eligible studies were published in the 
last decade (Tables 1-9). The first seriously studied polyphenol-rich product was Daflon, a 
flavonoid fraction of Rutaceae aurantiae containing the flavone diosmin and flavanone 
hesperidin, followed by the procyanidin-rich pine bark extract Pycnogenol. These two products 
have paved the way for other polyphenol-rich dietary products, such as olive oil, soy, berries, 
grape, wine, tea and cocoa to be studied in relation to microvascular function. Most clinical 
studies have focused on the skin microcirculation, which may probably be explained by its 
relatively easy accessibility. In the following sections the different sources of polyphenols 
tested on microvascular function are summarised in separate sections in alphabetical order. 
  
Berries (insert table 1 near this text)  
Berries are rich in polyphenols and contain phenolic acids, stilbenes and a variety of flavonoid 
subclasses, of which they are richest in anthocyanins. Limited studies have examined the 
effect of berries upon microvascular function (Table 1). In a randomised, double-blind, 
crossover, placebo-controlled acute study in a healthy population, a 20% blackcurrant juice 
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drink, likely to represent the dose consumed in a normal diet, did not demonstrate any 
immediate improvement in cutaneous endothelium-dependent and endothelium-independent 
vascular reactivity [74] assessed via acetylcholine (ACh) and sodium nitroprusside (SNP) 
iontophoresis with laser Doppler imaging (LDI). These results suggest that berries do not have 
any acute effect upon microvascular function in healthy volunteers, although further 
investigation is warranted given the lack of research to date.  
 
Individuals with non-medicated retinal vasculopathy, who typically exhibit impaired 
microvascular health, demonstrated significant improvements in ocular blood flow following 
chronic (6-months) supplementation with 160mg/day bilberry extract [75] compared to a 
control group receiving standard management only. Two standardised bilberry extracts were 
administered in a parallel group design, each containing 36% anthocyanins, but with one 
extract containing the full range of non-anthocyanin components as well. Both intervention 
groups demonstrated improvement in basal retinal blood flow velocity measured by high 
resolution colour Doppler imaging. Supplementation with the full range of non-anthocyanin 
components further improved retinal blood flow when compared to standard management. 
These studies may suggest that the impact of berries on microvascular health differs between 
healthy vs diseased, with a potential impact in a diseased population with a priori impaired 
vascular health. Although this fits with several previous observations of benefits of dietary 
interventions in populations at risk, we need to be careful since differences in methodological 
design between studies and the lack of properly designed, longitudinal studies prevent strong 
conclusions regarding the impact of berries on microvascular function.  
 
Cocoa (insert table 2 near this text) 
Consumption of a flavanol-rich cocoa beverage versus a low flavanol control beverage 
increased skin blood flow in healthy females when measured by LDF and spectroscopy [76]. 
Similarly, Heinrich and colleagues (2006) observed increased cutaneous blood flow after 6- 
and 12-weeks consumption of high- versus low-flavanol cocoa. A randomised, parallel-group 
study comparing the effects of 900mg daily cocoa flavanol consumption in healthy young and 
elderly male individuals demonstrated an increase in microvascular function for both groups, 
measured by forearm strain gauge plethysmography and reactive hyperaemia LDPI [78]. 
These observations in healthy subjects could not be replicated in those with cardiovascular 
disease and/or risk. Indeed, microvascular function was not affected 2-hours following 
consumption of flavonoid-rich dark chocolate in individuals with symptomatic peripheral artery 
disease when compared to a cocoa-free white chocolate control [79]. Also, prolonged use of 
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flavanol-rich cocoa treatment (2- or 6-weeks) in a randomized controlled trial did not 
significantly affect microvascular function in individuals with essential hypertension [80] or 
coronary artery disease [81]. Although this might suggest that flavanol-rich cocoa is more 
effective in improving microvascular function in healthy individuals, variability in assessments 
of the primary outcomes and/or the polyphenol dose may (at least partly) have contributed to 
these differences. 
 
In addition to skin blood flow, the effects of polyphenol-rich cocoa have been investigated on 
microvascular function in other organs. In agreement with the data derived from the skin, 
retinal vessel diameter dilation was observed 2h post cocoa-rich chocolate in individuals with 
glaucoma, but not in age-matched controls [82]. Furthermore, increased renal perfusion was 
observed in healthy individuals 2-hours post-consumption of cocoa-rich dark chocolate (70% 
cocoa) [83]. In studies that utilised MRI techniques, 5 days consumption of flavanol-rich 
cocoa (150mg daily) demonstrated increased CBF measured by BOLD-MRI in young, healthy 
males following a cognitive task [84]. Similar beneficial chronic effects of cocoa on regional 
cerebral perfusion (assessed via fMRI) were reported by Brickman et al. [85]. Furthermore, 
using arterial spin labelling fMRI, Lamport and colleagues (2015) reported increases in 
regional cerebral perfusion 2-hours following consumption of a high-flavanol versus low-
flavanol beverage in healthy, older (55-65) males. Current research, therefore, suggests that 
flavonoid-rich cocoa positively affects microvascular function in healthy individuals, in skin as 
well as in other tissues, whilst such effects were not observed in patient populations. 
Nonetheless, the lack of long-term studies examining the effects of flavonoid-rich cocoa 
prevents strong conclusions on the impact of cocoa on microvascular health. 
 
Daflon (insert table 3 near this text) 
Daflon is a micronized flavonoid fraction of Rutaceae aurantiae (citrus family) consisting of 
90% diosmin and 10% hesperidin. Some uncontrolled observational studies in chronic venous 
insufficiency patients have suggested beneficial effects of Daflon (1000 mg per day) on the 
cutaneous and capillary microcirculation [87, 88]. In randomised and placebo controlled 
studies improvements in lower limb venous distensibility and capacitance (via venous 
occlusion plethysmography) occurred in chronic venous insufficiency patients after chronic 
Daflon supplementation (1-week – 2-months) [89, 90]. Similar beneficial effects were also 
evident in healthy populations and/or healthy legs of patients with unilateral venous 
insufficiency [89, 91]. Galley and colleagues (1993) observed increased forearm capillary 
conductance in older individuals with symptomatic capillary fragility following both 4- and 6-
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weeks supplementation with S5682 flavonoid fraction, consisting of diosmin and hesperidin, 
compared to placebo control. Beneficial effects of Daflon have also been reported after acute 
administration of 1000mg in randomised and placebo controlled studies [89]. Overall, these 
results indicate a positive effect of Daflon on the peripheral microcirculation, particularly in 
individuals with compromised peripheral circulation. Whether Daflon also affects other patient 
populations prone to microcirculatory disorders is currently unknown.     
 
Grape and Wine (insert table 4 near this text) 
Polyphenol-rich grape are amongst the most frequently examined polyphenol-rich food 
products, and appear to improve microvascular function in the majority of studies. This 
observation matched with macrovessels, since red wine is associated with improved 
endothelial function in macrovessels [92, 93]. Regarding the microcirculation in healthy 
volunteers, it was found that daily consumption of grape juice for 3-weeks in a single arm trial 
of male, adult triathletes was associated with improved functional capillary density although 
no control trial was included [94]. Furthermore, a single arm trial in healthy women observed 
a borderline significant increase in forearm endothelium-dependent dilation (P=0.06), whilst a 
significant improvement in endothelium-independent vasodilation (P<0.01) was found 
following 3-weeks daily supplementation with red wine [95]. However, an acute single dose of 
red wine did not demonstrate any effect on forearm blood flow. In agreement with healthy 
subjects, a previous randomised, double-blind, placebo-controlled study of obese, male 
smokers, supplementation with grape seeds found improved skin blood flow at 4-weeks (but 
not at 8-weeks) compared to the control group [96]. In addition, the grape-derived product red 
vine leaf enhanced basal malleolar skin blood flow (Laser Doppler flowmetry) following 6-
weeks daily 360mg supplementation in a randomised, double-blind, cross over, placebo-
controlled study in individuals with chronic venous insufficiency [97]. Beneficial chronic effects 
of 16 weeks thrice daily grape juice on regional cerebral perfusion (assessed via fMRI) in older 
adults with mild cognitive impairment were reported by Krikorian and colleagues [98]. Despite 
these encouraging effects of grapes (products), further research is required to better 
understand their acute and longitudinal effects on microvascular function in both pathological 
and healthy populations.  
 
Olive Oil (insert table 5 near this text) 
The Mediterranean diet is associated with improved cardiovascular health and a major 
constituent of this diet is olive oil, which is rich in phenolic compounds [99]. In a study of older 
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(53-68yrs) hypercholesteraemic individuals, no difference was observed in digital 
microvascular function between acute ingestion of PPR olive oil and low phenol control olive 
oil [100]. In contrast, a two month randomised, double-blind, crossover study comparing the 
effects of polyphenol-rich (PPR) and polyphenol-free (PPF) olive oil in a young, female, mildly 
hypertensive population, demonstrated an increase in reactive hyperaemia following the PPR 
diet compared to baseline, whereas no change was observed after the PPF diet  [101]. This 
study adopted a 30mg/day dose, which is consistent with the quantity consumed as part of a 
normal diet. To date, no studies have been performed in healthy individuals. Taken together, 
whilst acute ingestion of olive oil has limited effects, regular consumption of olive oil is 
associated with improved microvascular health.  
 
Pine Bark (insert table 6 near this text) 
Nishioka and colleagues (2007) observed an increased FBF response to ACh following 2-
months of daily supplementation with Pycnogenol, a standardised extract from French 
maritime pine bark (Pinus pinaster Ait), in healthy males compared to placebo. Pycnogenol 
has been extensively studied in the treatment and prevention of venous microangiopathy, 
particularly chronic venous insufficiency (CVI) [103, 104]. In a randomised three-group design, 
individuals with severe CVI underwent assessment of cutaneous LDF derived resting flux in 
the perimalleolar region 8-weeks following a daily intervention of capsular Pynogenol 
150mg/day, Pycnogenol 150mg/day with compression stockings or compression stockings 
only [103]. Microvascular function improved following regular consumption of Pycnogenol, and 
Pycnogenol combined with compression stockings. These findings are supported by several 
further studies by the same research group that were undertaken in similar patient groups 
where improved cutaneous microvascular function was observed following 8-weeks 
supplementation with 150mg/day Pycnogenol versus placebo [105], 4-weeks supplementation 
versus placebo in individuals with severe diabetic microangiopathy [106] and 8-weeks of either 
150mg/day or 300mg/day Pycnogenol [107]. A further study by Hu and colleagues (2015) 
recently observed that 12-weeks supplementation with 150mg/day oral Pycnogenol increased 
basal LDF flux in pre-clinical, borderline hypertensive, hyperlipidemic and hyperglycemic 
individuals. Another research group also observed a beneficial effect of Pycnogenol on skin 
blood flow after 6-weeks in individuals with diabetic microangiopathy [109], essential 
hypertension [110] and CVI [111]. Collectively, these studies suggest that Pycnogenol 
demonstrates increased skin blood flow in a range of patient populations observed by several 
research groups.  
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The microvascular benefits of Pycnogenol supplementation are not confined to the skin. 
Pycnogenol consumed daily for 6-months had a beneficial effect on blood velocity of the 
cochlear artery in individuals with Meniere’s disease and moderate tinnitus [112]. Individuals 
with diabetic retinopathy and other vascular retinal diseases demonstrated improved retinal 
vascularisation and reduced endothelial permeability following a 2-month randomised, double-
blind, placebo-controlled, parallel group study where individuals received 150mg/day 
Pycnogenol [113]. Retinal blood flow was also increased following 3-months of Pycnogenol 
versus placebo in individuals with type 2 diabetes mellitus and moderate diabetic retinopathy 
[114].  
 
Studies have also explored the potential clinical benefits of oral consumption of Pycnogenol 
combined with topical application of Pycnogenol powder. In individuals with severe CVI, 
Belcaro and colleagues (2005) observed a significant difference in the transcutaneous partial 
pressure of oxygen (PO2) and partial pressure of carbon dioxide (PCO2) in the 6-week oral 
and oral combined with topical Pycnogenol groups versus control, with better venous ulcer 
healing in the combined group. A similar outcome was observed in a subsequent 6-week study 
in individuals with severe diabetic microangiopathy performed by the same research group 
[109], suggesting that oral and topical Pycnogenol could be a very useful treatment for 
individuals with microangiopathy. These observations in (pre-)clinical trials suggest that pine 
bark represents a useful non-pharmacological therapeutic treatment for improving 
microvascular function with potential clinical benefit.  
 
Pure Polyphenol Compounds (insert table 7 near this text) 
The number of studies that have examined the effects of pure polyphenol compounds on 
microvascular function is limited. Most studies have evaluated the effects of resveratrol. From 
the four studies conducted to date, resveratrol has demonstrated no acute improvements in 
cerebral microvascular function compared to placebo control [115, 116], with the exception of 
an acute increase in total haemoglobin in the pre-frontal cortex measured by NIRS [117]. 
However, the same study observed no significant difference after four weeks supplementation. 
Gliemann and colleagues (2014) showed actually that training-induced angiogenesis of 
skeletal muscle capillaries was limited following resveratrol supplementation. In conclusion, 
there is insufficient evidence to suggest that resveratrol beneficially affects the 
microcirculation. Each of the four resveratrol studies were performed in a healthy population 
so the effects of resveratrol in a pathological population remain unknown.  
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In line with resveratrol, other pure polyphenol compounds were unable to increase cerebral 
perfusion. Epigallocatechin gallate, the most abundant flavonoid in green tea, was not 
associated with any increase in cerebral blood flow in the prefrontal cortex following either a 
135mg or 270mg dose in an acute study of young, healthy adults [119]. The 135mg dose was 
associated with reduced CBF following cognitive task performance which highlights how 
observing microvascular changes under a challenged condition can confound results and 
make interpretation of findings more difficult, particularly when there is limited research 
examining the effects in baseline conditions. When examining pure polyphenol compounds 
on peripheral vascular beds, dispersible hesperetin, an aglycone of citrus flavonoids, 
demonstrated a beneficial effect upon cutaneous microvascular function in a study of young, 
healthy females with cold sensitivity [120]. Overall, there appears to be mixed evidence for 
improvements in microvascular function following supplementation with pure polyphenol 
compounds. As several studies have so far been undertaken by a single research group, it 
would be advantageous for multiple research centres to address this gap in our current 
knowledge of the microvascular consequences of pure polyphenol supplementation.  
 
Soy (insert table 8 near this text) 
Three studies have examined the effect of soy in post- and peri-menopausal populations. 
These groups were chosen since isoflavones within the soy bean have a similar chemical 
structure to the estrogen hormone estradiol [121]. Various measures of microvascular function 
have been used to examine the effect of soy, with Wong and colleagues (2012) observing no 
significant difference in forearm blood flow when measured via strain-gauge plethysmography 
and peak reactive hyperaemia after 80mg daily supplementation with soy tablets for 6-weeks. 
Similarly, no differences were observed for laser Doppler velocimetry [122] or forearm venous 
occlusion plethysmography response to ACh or SNP [123] after 55mg daily soy capsules for 
6-weeks and 80mg daily soy tablets for 5-10-weeks, respectively. It seems relevant that these 
observations were made in patient groups, who all demonstrated impaired vascular health 
prior to the start of the intervention. This provides further support that soy unlikely has benefits 
in improving microvascular health. 
 
Tea (insert table 9 near this text) 
Macrovascular function is generally improved following the consumption of polyphenol-rich 
tea. In agreement with larger vessels, some evidence now also supports the benefits of acute 
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as well as chronic tea consumption on skin blood flow. Fuchs and colleagues (2016) recently 
observed the ability of tea to prevent the increase in postprandial vascular resistance of 
forearm microvessels within 3-hours following 100ml black tea in a randomised, cross-over 
study in obese, insulin-resistant males. Heinrich and colleagues (2011) performed an acute, 
double-blind trial in 15 healthy females who were randomised into 3 groups, each of whom 
received a single dose of capsular green tea extract (0.5, 1.0 or 2.0g). Skin blood flow after all 
three doses increased at 15-30-min with no difference between doses. A further acute pilot 
study by Miller and colleagues (2011) investigated the effect of capsular green tea extract 
(836mg green tea catechins) on laser Doppler responses to ACh and SNP iontophoresis in 
healthy, non-smoking, overweight individuals, but found no impact of tea. Overall, these 
studies on the acute effects of tea suggest that flavonoid-rich tea has the capacity to acutely 
increase microvascular function. In line with these observations, a 12-week double-blind, 
placebo-controlled study in 60 middle-aged, healthy females observed increased forearm 
cutaneous blood flow at both the midpoint and end of the 12-week intervention for green tea 
consumption [125]. Oxygen saturation of haemoglobin was also increased at 6- and 12-weeks 
following daily consumption of the green tea beverage. However, regular consumption of 
capsular green tea for 3-weeks was not associated with any difference in endothelium-
dependent or endothelium-independent microvascular reactivity in a double-blind, placebo-
controlled parallel study in healthy males [127]. Furthermore, Vidyasagar and colleagues 
(2013) observed no effect of black tea on cerebral blood flow 2-hours after consumption in 
healthy males (assessed by fMRI).  
 
The nature of the intervention product may be responsible for some of the differences in 
microvascular function observed in these studies of healthy individuals. Studies that used a 
beverage seem to show a benefit in improved microvascular function, whilst such effects were 
not found when using a capsular form of tea. This may be due to the capsular shell material 
hampering bioavailability, as cellulose based shells and fillers are known to have a negative 
interaction with polyphenols [129]. To support this idea, gelatin capsules without a cellulose 
filler demonstrate more positive outcomes. However, precise details are scarce regarding the 
shell and filler materials of capsules used in the studies discussed, so it is difficult to establish 
whether this may be a causal factor for the apparent differences between studies and their 
intervention products.  
 
The microvascular effects of green tea have also been examined in individuals with increased 
cardiovascular disease risk. Smoking is associated with impaired endothelial function, even 
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when individuals are otherwise healthy [130, 131]. With this in mind, Oyama and colleagues 
(2010) investigated whether daily consumption of green tea catechins for 2-weeks 
demonstrated any effect on forearm blood flow (FBF) responses to ACh and SNP in healthy, 
male smokers. Individuals were divided into three groups receiving daily green tea catechins: 
control (0mg), medium-dose (80mg) or high-dose (580mg). FBF was assessed acutely (2h), 
at the mid-stage (day-7) and at the end of the trial period (day-14). The acute response to ACh 
was increased for the high-dose group, but no difference was observed for the medium-dose 
or control groups. No significant acute response to SNP was observed for any group.  Similar 
to the acute responses, chronic consumption of green tea catechins was associated with 
significantly increased FBF responses to ACh for the high-dose group, but not for the medium-
dose or control groups and no difference was observed for any group in response to SNP. 
These findings suggest an endothelium-dependent vasodilatory response for high-dose green 
tea catechins, both acutely and following regular consumption. This improvement in 
endothelial function is encouraging for green tea having a positive effect upon cardiovascular 
health in at-risk populations. Further studies are required to explore these effects further.  
 
Summary Discussion 
(insert table 10 near this text) 
This systematic review highlights the effects of polyphenol-rich dietary sources on 
microvascular function. Due to the wide range of microvascular networks and various 
polyphenolic dietary sources, it has previously been difficult to establish any conclusions on 
this topic. Our robust methodology, systematically reviewing all publications on polyphenols 
and microcirculation, has enabled us to provide valuable insight into this important area of 
research and to identify where future research is required. Whilst it is difficult to determine the 
effects of some subgroups due to limited clinical studies, flawed statistics and mixed evidence 
likely related to small sample sizes and variable measurement techniques, precluding a more 
definitive indicator of overall microvascular effects, the review suggests that some polyphenol 
sources do improve microvascular function (see Table 10). Consistent improvement in 
microvascular function were observed with Pycnogenol and Daflon. Promising effects were 
observed for cocoa (in healthy subjects), black and green tea (consumed as beverage) and 
grape products (grape juice and red wine). These results suggest that different subtypes of 
polyphenols may benefit the microcirculation. The number of studies conducted with isolated 
pure polyphenols is too limited indeed to declare superiority in efficacy of one polyphenol 
(subtype) over another. Larger, well designed studies are required to further our collective 
knowledge of the microvascular effects of dietary polyphenols in all subgroups.  
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Limitations  
Currently there is insufficient data for a single measure of microvascular function to enable us 
to perform a meta-analysis which would provide a more precise analysis of the microvascular 
effects of polyphenols. A further limitation of this review is that there is an absence of analysis 
to determine the potential mechanisms underlying any beneficial effects of polyphenol-rich 
dietary sources upon microvascular function. However, this is beyond the scope and original 
aims of the review. 
 
Conclusion  
Overall, consumption of polyphenol-rich foods and beverages demonstrate improved 
microvascular function, although this is dependent upon the polyphenol source, the dose of 
the product, the duration of consumption and the population group studied. Most subgroups 
reviewed suggest an overall beneficial effect on microvascular function, particularly grape-
derived products, cocoa, tea, pine bark and Daflon. Other groups (berries, olive oil, soy and 
pure polyphenol compounds) remain equivocal and require further study due to the limited 
research performed to date. Polyphenols are abundant in the human diet and this systematic 
review demonstrates that they are an inexpensive, non-pharmacological approach for 
improving cardiovascular health in currently healthy individuals and in populations with 
microvascular dysfunction. It can be expected that such improvements may contribute to lower 
risk for the development of future cardiovascular disease.  
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FIGURE LEGENDS 
 
Graphical Abstract.  
Figure 1. An overview of the techniques used to measure microvascular function.  
Figure 2. Dietary polyphenol subclasses, their basic chemical structure and typical dietary 
sources.  
Figure 3. A flowchart of the methodology used for identifying studies and screening for their 
eligibility in the systematic review.  
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Table Legends  
Table 1. Berries: characteristics of the studies included for review.  
Table 2. Cocoa: characteristics of the studies included for review.  
Table 3. Daflon: characteristics of the studies included for review.  
Table 4. Grape and Wine: characteristics of the studies included for review.  
Table 5. Olive Oil: characteristics of the studies included for review. 
Table 6. Pine Bark: characteristics of the studies included for review. 
Table 7. Pure Polyphenol Compounds: characteristics of the studies included for review. 
Table 8. Soy: characteristics of the studies included for review. 
Table 9. Tea: characteristics of the studies included for review.  
Table 10. Summary of polyphenol sources and their acute and chronic effectiveness in 
improving microvascular function.   
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Table 1: Berries. 
Author  Product Polyphenol 
Dose 
Control Population1 Study 
Design2 
Study 
Duration  
Microcirculation 
Target3 
Outcome Measures4 
Active Control 
[75] Mirtoselect (Mi) 
& generic 
bilberry extract 
(GBE) 
(both 36% 
anthocyanins) 
160 mg/day 
bilberry extract 
(both Mirtoselect 
& generic 
bilberry extract 
with 36% 
anthocyanins) 
No 
supplement  
Diabetics with 
retinopathy 
2 groups: 
Hyperflow & 
ischemic 
n=140 
Mi: n=47, 44y; 
GBE: n=55, 
44y; C: n=38, 
45y 
Open-label, 
registry, 
supplement 
study 
6 months Retina 
High resolution 
colour Doppler 
imaging central 
retinal artery  
Peak systolic/diastolic 
flow velocity (cm/s) 
Hyperflow:  
Mi: 24±2/12±1*  
GBE: 28±3/16±3  
Ischemic:  
Mi: 23±2/14±2*  
GBE: 19±2/11±1*  
*p<0.05 vs Control,  
Peak systolic/diastolic 
flow velocity (cm/s) 
Hyperflow:  
28±3/15±3  
 
Ischemic: 
17±2/12±1  
 
[74] Blackcurrant 
juice drink 
250 ml drink 
(20% 
blackcurrant) 
250 ml drink H 
n=20, 44.6y 
45% M 
R, C, DB 
(4 week 
washout) 
Acute 
(0-2h) 
Skin (site not 
specified). 
Vascular reactivity, 
LDI, ACh, SNP  
 
(PU)  
ACh: 52±149  
SNP: 251±273  
(ns vs. Control)  
(PU)  
ACh: 189±129  
SNP: 209±472  
1 H, healthy; M, males; 2 C, crossover trial; DB, double blind; R, randomised; 3 ACh, acetylcholine; LDI, laser Doppler imaging; SNP, sodium nitroprusside; 4 cm/s, centimetres per second; ns, not 
significant; PU, perfusion units.   
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Table 2: Cocoa.  
Author  Product Polyphenol 
Dose 
Control Population1 Study 
Design2 
Study 
Duration  
Microcirculation 
Target3 
Outcome Measures4 
Active Control 
[78] Cocoa drink 
(450 mg 
flavanols) 
900 mg daily Nutrient 
matched 
cocoa-free 
drink (0 mg 
flavanols) 
H, NS 
 
Young: n=22, 
26y (<35y), 
100% M 
+ 
Elderly: n=20, 
60yrs (50-80y), 
100% M 
 
 
R, DB, P 2 weeks 
+ Acute (1h) 
Skin: FBF, VOP, 
RH, LDPI 
Young 
Acute, chronic, acute-on 
chronic:  
FBF (ml/100ml*min)  
1.8±0.1, 1.8±0.1, 1.8±0.1  
FBF max (ml/100ml*min) 
18.2±1.0, 18.9±0.8, 18.9±1.1  
LDPI (PU) 40±1, 39±1, 40±1  
LDPI max (PU) 292±15, 
307±14, 298±17  
 
Elderly 
Acute, chronic, acute on 
chronic:  
FBF (ml/100ml*min)  
1.2±0.1, 1.1±0.1, 1.1±0.0  
FBF max (ml/100ml*min) 
12.3±1.5^*, 14.0±1.4^*, 
13.9±1.1^* 
LDPI (PU) 39±0, 40±1, 39±1  
LDPI max (PU) 200±14^*, 
214±12^*, 213±12^*  
  
^p<0.05 vs Young for same 
time point and intervention 
group *p<0.05 vs Control in 
same group 
Young 
Acute, chronic, acute-on 
chronic:  
FBF (ml/100ml*min)  
1.5±0.1, 1.5±0.1, 1.4±0.1  
FBF max (ml/100ml*min) 
14.3±1.8, 13.7±1.7, 13.8±1.5 
LDPI (PU) 42±1, 42±1, 39±1   
LDPI max (PU) 270±17, 
260±22, 258±17  
 
Elderly 
Acute, chronic, acute on 
chronic:  
FBF (ml/100ml*min)  
0.9±0.1, 0.8±0.0, 0.9±0.0  
FBF max (ml/100ml*min) 
10.8±1.5^, 11.6±1.7^, 
11.0±1.5^ 
LDPI (PU) 44±0, 39±1, 40±1   
LDPI max (PU) 186±8^, 
178±5^, 180±5^  
 
^p<0.05 vs Young for same 
time point and intervention 
group 
[79] Flavonoid-rich 
dark chocolate 
50 g Cocoa-free 
white 
chocolate (50 
g) 
Symptomatic 
PAD (Fontaine 
stage II) 
n=21, 66.9y 
17% M 
R, SB 
(investigator), 
C 
Acute: 2h 
7-day washout 
Laser Doppler: RH Perfusion (AU)  
0.31 (0.25-0.55) (ns)  
Biological zero (AU) 
0.14 (0.12-0.16) (ns)  
Time to peak perfusion (s)  
25 (10-48) (ns)  
Peak perfusion (AU) 
1.18 (0.70-2.27) (ns)  
Recovery time (s)  
136 (107-172) (ns)  
Perfusion (AU) 
0.41 (0.24-0.51) (ns)  
Biological zero (AU) 
0.15 (0.09-0.19)*  
Time to peak perfusion (s) 
26 (18-42) (ns)  
Peak perfusion (AU) 
1.24 (0.85-1.79) (ns)  
Recovery time (s)  
140 (104-165) (ns)  
*p=0.01 within group 
difference  
[82] Polyphenol-
rich dark 
chocolate 
40 g dark 
chocolate 
White 
chocolate 
Glaucoma 
n=60 (30 + 30 
age-matched 
controls) 
65y 
R Acute (2h) Retina: diameter – 
static & dynamic 
vessel analysis (right 
eye only) 
Glaucoma patients 
CRAE (µm) 169±9 (ns)  
CRVE (µm) 192±15 (ns)  
AV ratio 0.88±0.07 (ns)  
Dilation arterioles (%)  
Glaucoma patients 
CRAE (µm) 171±18  
CRVE (µm) 206±15  
AV ratio 0.83±0.06  
Dilation arterioles (%)  
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 3.3±1.9 (ns)  
Constriction arterioles (%)  
0.4±1.3 (ns)  
Dilation venules (%)  
5.0±2.1 (ns)  
 
Age-matched controls  
CRAE (µm) 179±13 (ns)  
CRVE (µm) 205±17 (ns)  
AV ratio 0.87±0.06 (ns)  
Dilation arterioles (%)  
3.5±1.8 (ns)  
Constriction arterioles (%)  
-0.6±1.1 (ns)  
Dilation venules (%)  
4.2±1.4* 
*p=0.01 vs Control  
3.0±1.7  
Constriction arterioles (%)  
-0.8±1.3  
Dilation venules (%)  
4.2±1.8  
 
Age-matched controls  
CRAE (µm) 183±12  
CRVE (µm) 208±20   
AV ratio 0.88±0.07  
Dilation arterioles (%)  
2.6±1.9  
Constriction arterioles (%)  
-0.3±1.2  
Dilation venules (%)  
3.4±1.9 
 
[83] Cocoa rich 
dark chocolate 
1 g dark 
chocolate 
(70% cocoa) 
per kg body 
weight (50-80 
mg 
polyphenols) 
Flavonoid poor 
white 
chocolate (4% 
cocoa) 
H, preserved 
kidney function 
n=10, 35y 
30% M 
CO, pilot study Acute (2h) Renal tissue 
oxygenation: BOLD 
fMRI. Low R2* 
estimate of high pO2 
in renal tissue 
Medullary R2*  
Baseline vs 2 h (s)  
29.6±1.3 vs 28.2±1.3  
(p=0.04) 
Cortical R2* not changed 
Medullary R2* 
Baseline vs 2 h (s)  
29.0±2.1 vs 28.9±1.7 (ns) 
 
Cortical R2* not changed 
[80] Flavanol-rich 
cocoa drink 
~900 mg/day Isocaloric, 
nutrient 
matched  
flavanol-poor 
cocoa drink 
(~28 mg/day) 
H, mild-to-
moderate 
hypertension 
n=20, 51y 
40% M 
R, DB, C 2 weeks per 
intervention  
(1 week 
washout)  
Forearm skeletal 
muscle capillary 
recruitment / blood 
flow: microbubble 
contrast-enhanced 
US 
Capillary blood flow (AU) 
Baseline vs cocoa  
0.45±0.06 vs 0.51±0.07 (ns)  
Steady state insulin infusion 
(AU) 0.76±0.09 vs 0.74±0.09 
(ns)  
Insulin-induced change from 
baseline (%)  
123±35 vs 77±24 (ns)  
Capillary blood flow (AU) 
Baseline vs placebo  
0.45±0.06 vs 0.68±0.23 
Steady state insulin infusion 
(AU) 0.76±0.09 vs 0.67±0.11  
Insulin-induced change from 
baseline (%)  
123±35 vs 309±220 
[76] High flavanol 
cocoa drink 
100 ml drink 
(329 mg 
flavanols) 
Low flavanol 
cocoa drink 
(27 mg 
flavanols) 
H 
n=10, 0% M 
C Acute 
(0-6h) 
Skin (1mm depth): 
LDF & spectroscopy 
High flavanol:  
Baseline vs 2h (AU) 
30.08±11.40 vs 49.26±9.26* 
*p<0.05 compared to low 
flavanol group 
Low flavanol:  
Baseline vs 2h (AU) 
23.14±17.02 vs 23.40±10.74 
 
[77] High flavanol 
cocoa 
329 mg/day 
(61 mg/day 
epicatechin + 
20 mg/day 
catechin) 
Low flavanol 
cocoa 27 
mg/day (6.6 
mg/day 
epicatechin 
+1.6 mg/day 
catechin) 
H, type II normal 
skin 
n=24, 18-65y, 
0% M 
R, DB, P 12 weeks  Skin: cutaneous 
(1mm) + 
subcutaneous (7-
8mm). 
O2C system (LDF + 
tissue spectrometry) 
Baseline (AU): 
Cutaneous 16±7 
Sub-c 133±57 
6weeks (AU): 
Cutaneous 24±12*^ 
Sub-c 155±61* 
12weeks (AU):  
Cutaneous 32±16*^ 
Sub-c 183±66*^ 
*p<0.05 vs wk 0  
Baseline (AU): 
Cutaneous 17±9 
Sub-c 144±45 
6weeks (AU): 
Cutaneous 17±6 
Sub-c 134±50 
12weeks (AU):  
Cutaneous 16±6 
Sub-c 131±47 
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^p<0.05 vs Control 
[84] Flavanol-rich 
cocoa drink 
1 drink/day 
(172 mg 
flavanols per 
drink) 
Low flavanol 
cocoa drink 
(13 mg 
flavanols per 
drink) 
H 
n=16 
18-30y 
100% M 
DB, CB 
 
 
5 days Cerebral: fMRI 
BOLD responses to 
cognitive task 
(% change from baseline) 
DLPFC: 3.0±0.2 
PC: 2.5±0.2 
ACC: 2.1±0.3 
 
(% change from baseline)  
DLPFC: 2.3±0.2 
PC: 2.1±0.3 
ACC: 1.7±0.1 
[81] Flavanol-rich 
chocolate bar 
+ cocoa 
beverage 
444 mg/day 
total flavanols 
Isocaloric 
placebo bar + 
beverage 
(19.6 mg/day 
total flavanols) 
CAD 
n=40, 61y 
75% M 
R, DB, 
placebo-
controlled 
6 weeks  Forearm blood flow: 
VOP 
2-min wrist exercise 
+ 5-min ischemia 
protocols 
 
(mL/min) 
Exercise  
Resting FBF: 2.2±0.2 
Peak FHBF: 24.9±2.2 (ns)  
 
Ischemia 
Resting FBF: 2.5±0.2 
Peak RHBF: 30.4±1.7 
(ns)  
(mL/min) 
Exercise 
Resting FBF: 2.5±0.3 
Peak FHBF: 23.1±1.8 
 
Ischemia 
Resting FBF: 2.8±0.4 
Peak RHBF: 28.1±1.8 
 
1 CAD, coronary artery disease; H, healthy; M, male; NS, non-smokers; PAD; peripheral artery disease; 2 C, crossover trial; CB; counterbalanced; DB, double blind; P, parallel arms; R, randomised; SB, 
single blind; 3 BOLD, blood oxygenation level-dependent; FBF, forearm blood flow; fMRI, functional magnetic resonance imaging; LDF, laser Doppler flowmetry; LDPI, laser Doppler perfusion imaging; 
pO2, partial pressure of oxygen; RH, reactive hyperemia; US, ultrasonography; VOP, venous occlusion plethysmography; 4 ACC, anterior cingulate cortex; AU, arbitrary units; AVR, arterio-venous ratio; 
CRAE, central retinal artery equivalent; CRVE, central retinal vein equivalent; DLPFC, dorsolateral prefrontal cortex; FBF, forearm blood flow; mL/min, FHBF, forearm hyperaemic blood flow; ns, not 
significant; PC, parietal cortex; PU, perfusion units; RHBF, reactive hyperaemic blood flow; s, seconds.   
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Table 3: Daflon.  
Author Intervention 
Product 
Polyphenol 
Dose 
Control Population1 Study 
Design2 
Study 
Duration  
Microcirculation 
Target3 
Outcome Measures4 
Active Control 
[133] Daflon 500 mg 
twice daily 
None mild to moderate 
CVI 
n= 28, 56±13 y, 
46% M 
Observational 6 months  
(pre vs post) 
Air plethysmography Mean calf circumference 
(cm)  
37.0 ±4.3 vs 36.4 ±4.3 
(p<0.001) 
Venous filling index (mL/s) 
3.7 ±3.5 vs 3.4 ±2.5 (ns) 
Ejection fraction (%)  
54.5±15.9 vs 57.7±19.7 
(ns) 
Residual volume fraction 
(%)  
41.4±19.2 vs 39.4±24.2 
(ns) 
N/A 
[134] Daflon 500 mg 
twice daily 
None CVI: 
+/- venous reflux 
n= 3,075 
46 y, 16% M 
Observational 6 months  
(pre vs post) 
Leg circumference With venous reflux (cm)  
27.99 vs 26.51 (p=0.0001) 
Without venous reflux (cm)  
28.61 vs 27.28 (p=0.0001) 
N/A 
[135] Daflon 500 mg 
twice daily 
 
Placebo Diabetics (18 
Type 1 and 22 
Type 2) 
49±15 y 
53% M 
R, DB, P 30-42 days  
(0 vs 30-42 
days) 
Capillary filtration of 
albumin (upper arm) 
(%) 
19.8±8.5 vs 6.7±8.9 
(p<0.001)  
(p<0.015 vs Control Post) 
(%)  
17.8±7.0 vs 13.6±9.8 
(p=0.046) 
[136] Daflon  
(500 mg 
tablets) 
500 mg 
1000 mg 
2000 mg 
None Mild CVI 
n= 104 
44±13 y 
4 % M 
R, DB, P 90 days  
(0, 28 and 90 
days) 
Lower limb LDV, % 
change from day 0 
(baseline, 
orthostasis, 
venoarteriolar reflex 
flux) 
 
 
Change in baseline (%) 
(day 90) 
0.00±0.48 (500 mg) 
0.08±0.66 (1000 mg) 
-0.34±1.02 (200 mg)  
(all ns) 
Change in orthostatic flux 
(%) (day 90) 
-0.08±0.24 (500 mg) 
-0.01±0.32 (1000 mg) 
-0.15±0.55 (2000 mg)  
(all ns) 
Change in venoarteriolar 
reflex (%) (day 90) 
5.72±17.14 (500 mg) 
2.75±21.77 (1000 mg) 
1.07±15.40 (2000 mg)  
(all ns) 
N/A 
[88] Daflon 2 x 500 mg 
(50 mg 
hesperidin) 
daily 
None CVI 
n= 25 
55±16 y 
19% M 
Observational 28 days  
(1 and 28 
days) and 14 
day washout 
Ankle skin dynamic 
capillaroscopy: RBC 
velocity and. 
intravenous injection 
Day 1 vs 28 
Basal RBC velocity 
(mm/sec)  
N/A 
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of vital dye for 
venous appearance 
and disappearance 
0.26±0.14 vs 0.35±0.11  
(p=0.024) 
Washout: 0.33±0.16  
Appearance time dye (s)  
23.1±7.8 vs 23.7±10.2 (ns) 
Disappearance time dye 
(min)  
26.1±3.4 vs 26.0±3.6 (ns) 
[90] Daflon 2 x 500 mg 
per day 
Nonmicronized 
diosmin 
CVI 
n= 88 
42±12 vs 42±11 
y 
30 vs 45% M 
R, DB, P 60 days  
(0 and 60 
days) 
VOP 
Max increase 
venous volume, time 
to reach max, max 
volume to void, total 
time emptying, 
venous distensibility 
 
Venous volume 
(mL/100mL)  
3.31±0.91 vs 2.60±0.72 
(p<0.01; p=0.003 vs 
Control 
Time max (s)  
200.5±41.3 vs 168.3±32.1 
(p<0.01; ns vs Control) 
Max volume to void 
(mL/100mL/min) 
61.9±20.3 vs 59.3±16.4 
(ns; ns vs Control 
Total time emptying (s)  
107.5±87.2 vs 95.3±62.9 
(ns; ns vs. Control)  
Venous distensibility 
(dV/dP)  
0.06±0.00 vs 0.04±0.00 
(p<0.01; p<0.001 vs 
Control) 
Venous volume (mL/100mL) 
3.17±1.00 vs 2.88±0.94 
(p<0.01) 
 
 
Time max (s)  
188.5±51.6 vs 165.3±44.3 
(p<0.01) 
Max volume to void 
(mL/100mL/min)  
62.7±17.4 vs 63.3±19.4 (ns) 
 
Total time emptying (s)  
102.3±65.7 vs 93.7±46.9 
(ns) 
Venous distensibility (dV/dP) 
0.06±0.00 vs 0.05±0.00 
(p<0.01) 
[137] S 5682 
flavonoid 
fraction 
(diosmin & 
hesperidin) 
1000 mg per 
day 
micronized 
diosmin 
(90%) & 
hesperidin 
(10%) 
Placebo, not 
specified 
Symptomatic 
capillary fragility 
n=100 
67y, 42% M 
R, DB, P 6 weeks  Forearm. Capillary 
resistance (negative 
pressure induced 
no. of petechiae) 
(mmHg)  
4 wks 219±10  
6 wks 261±12  
(both p<0.001 vs Control) 
 
(mmHg)  
4 wks 159±8  
6 wks 163±9  
 
[89] 
 
 
 
Daflon 500 mg 
 
 
 
 
 
 
 
 
 
 
 
 
Placebo 
 
 
 
 
 
 
 
 
 
 
 
 
Unilateral Post-
thrombotic 
Syndrome 
(diseased leg vs 
healthy leg) 
n= 20 
 
 
 
 
 
 
 
R, DB, C 
 
 
 
 
 
 
 
 
 
 
 
 
Acute  
(2 hours) 
 
 
 
 
 
 
 
 
 
 
 
VOP 
Venous capacitance 
(Hmax 50) 
Venous distensibility 
(ΔV) 
Venous emptying 
(Total emptying time 
(Tt), Emptying time 
of 1st half of Hmax 
(T50), Emptying time 
of 2nd half of Hmax 
(T2p)) 
Hmax 50 
Healthy leg 
Hmax 50: -1.9% (p<0.001 
vs Control) 
ΔVmax 40: -2.1%  
ΔVmax 50: -1.6%  
ΔVmax 60: -1.9%  
All p<0.001 vs. Control 
Tt: -1.5s (p=0.004 vs 
Control) 
T50: -1 s (ns vs Control) 
T2p: -1.5 s (p=0.005 vs  
Control) 
 
Healthy leg 
Hmax 50: +0.6%  
 
ΔVmax 40: -0.4%  
ΔVmax 50: 0.0%  
ΔVmax 60: +0.4%  
 
Tt: +0.3s  
 
T50: +0.3s  
T2p: +0.2 s  
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Vmax 50 
 
 
 
 
 
Diseased Leg 
Hmax 50: (-2.4% p<0.001 
vs control) 
ΔVmax 40: -1.2% 
(p=0.013 vs Control) 
ΔVmax 50: -1.6%  
ΔVmax 60:-1.9%  
Both p<0.001 vs Control 
Tt: -1.7s (p<0.001 vs. 
Control) 
T50: -0.5 s (ns) 
T2p : -1.8 s (p=0.001 vs 
Control) 
Venous Distensibility 
3.59 ΔVmax 50 at +2 
hours (p<0.01 vs Control) 
Diseased Leg 
Hmax 50: +0.4% 
 
ΔVmax 40: +0.2%  
 
ΔVmax 50: 0.0%  
ΔVmax 60: +0.6%  
 
Tt: +0.5s  
 
T50: +0.4s  
T2p: +0.6 s  
 
Venous Distensibility 
ΔVmax 50: 3.68  
Daflon 500 mg and 
500 mg per 
day 
Placebo 
 
H 
n=10 
R, DB, C 
 
0-24 hours 
and 1 week 
VOP 
 
3.55 ΔVmax 50 at +2 
hours after 1 week (p<0.01 
vs Control) 
3.67 ΔVmax 50 at +2 hours 
after 1 week 
Daflon 500 mg 
 
Placebo 
 
Venous 
insufficiency 
(females) 
Functional 
venous 
insufficiency 
 
Pregnant 
 
Post-thrombotic 
syndrome 
n= 20 
R, DB, C 
 
Acute 
(1 and 2 
hours) 
 
VOP 
 
2 hours  
Mean venous capacitance 
(Hmaxmm) 
26.3±0.5 vs 24.3±0.4 
(p<0.01) 
 
29.9±0.5 vs 27.9±0.5 
(p<0.01) 
 
30.4±1.0 vs 27.8±1.0 
(p<0.01) 
 
 
Not reported 
 
 
 
 
Not reported 
 
 
Not reported 
 
Daflon 500 mg per 
day 
 
Placebo 
 
Functional 
chronic venous 
insufficiency 
n=18 
R, DB, P 30 and 60 
days 
VOP 60 vs 0 days  
Mean venous capacitance 
(Hmaxmm) 
30.2 vs 29.4 (p<0.001) 
 
Venous emptying (s)  
28.1 vs 27.6 Tts (ns) 
2.39 vs 2.39 T50 (ns) 
25.7 vs 25.2 T2ps (p<0.01) 
 
Mean change in ankle 
perimeter (cm)  
24.31±0.49 vs 23.91±0.46 
(p<0.001) 
60 vs 0 days 
Mean venous capacitance 
(Hmaxmm) 
30.5 vs 30.4 (ns) 
 
Venous emptying (s)  
27.7 vs 27.8 Tts (ns) 
2.39 vs 2.39 T50 (ns) 
25.3 vs 25.4 Tts (ns) 
 
Mean change in ankle 
perimeter (cm)  
24.80±0.30 vs 24.81±0.31 
(ns) 
[87] Daflon 2 x 500 mg 
daily 
None Diabetics with 
microcirculatory 
disorders (7 with 
Observational 1 month (6 
months after 
treatment 
Capillary filtration of 
albumin (upper arm) 
Day 0 vs day 28 (%) 
12.8±1.6 v -1.4±0.5 
(p<0.05 vs Day 0) 
N/A 
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retinopathy, 7 
with peripheral 
neuropathy, 6 
with HT) 
n= 13, 55±3 y, 
31% M 
cessation in 
10) 
6 months post (%)  
8.4±1.8 (ns vs day 0) 
[138] Daflon tablets 
(450 mg 
diosmine and 
50 mg 
hesperidin) 
2 x 500 mg 
daily 
None n= 18 patients 
(n=11 varicose 
veins, n=7 
venous ulcers) 
 
 
Observational 3-4 weeks Photo-
plethysmography; 
Skin Perfusion 
Pressure  
(% of arterial BP)  
Varicose veins 
86.5±12.3 vs 91.3±13.3  
Venous ulcers 
68.4±7.2 vs 80.2±4.6  
No statistics reported 
N/A 
[91] Daflon 2 x 500 mg 
(50 mg 
hesperidin) 
Acute and 
daily for 7 
days 
 
 
 
 
 
 
 
 
Placebo 
 
H 
n= 10 
32±1 y 
0% M 
 
 
R, DB, C 
 
 
 
 
 
 
 
 
 
1-24 hours at 
Day 1, 8 
 
 
 
 
 
 
 
 
 
 
 
VOP (calf) 
Venous capacitance 
(Hmax 50) 
Venous distensibility 
(ΔV) 
Venous emptying 
(Total emptying time 
(Tt), Emptying time 
of 1st half of Hmax 
(T50), Emptying time 
of 2nd half of Hmax 
(T2p)) 
Hmax 50 
Vmax 50 
Day 1 
No data reported 
 
Day 8  
Baseline, 2h, 24h 
Hmax 50: 30.6, 30.0, 30.4  
(all p<0.05 vs Control) 
Vmax 50: 36.2, 35.5, 36.1  
(all p<0.05 vs Control) 
 
 
 
Day 8  
Baseline, 2h, 24h 
Hmax 50: 31.1, 31.1, 31.1 
 
Vmax 50: 36.7, 36.7, 36.7 
 
 
[139] Daflon 2 x 500 mg 
daily 
idiopathic cyclic 
oedema 
n= 30 
 
R, DB 6 weeks Capillary filtration of 
albumin (upper arm) 
 
(%)  
18.0±2.4 vs 5.5±2.5 
(p=0.02 vs Control) 
(%)  
14.8±1.4 vs 12.5±2.6  
1 CVI, chronic venous insufficiency; H, healthy; M, male; 2 C, crossover trial; DB, double blind; P, parallel arms; R, randomised; SB, single blind; 3 LDV, laser Doppler velocimetry; RBC, red blood cell; 
VOP, venous occlusion plethysmography; WO, wash-out; 4 BP, blood pressure; ns, not significant.   
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Table 4. Grape Products.  
Author  Intervention 
Product 
Polyphenol 
Dose 
Control Population1 Study Design2 Study 
Duration  
Micro-circulation 
Target3 
Outcome Measures4 
Active Control 
[96] Grape seeds 
(monomeric & 
oligomeric 
flavanols) 
200 mg/day Microcrystalline 
cellulose 
Non-obese, S 
(≥10 
cigarettes/d for 
5+ y) 
n= 28 
47y 
100% M 
R, DB, P 8 weeks  Skin, LDF  
ED50ACh, ACh dose 
required for 50% of 
max response 
(units not stated)  
Baseline 
5 (2–7) (ns) 
4wks 
4 (3–6)(p<0.05) 
8wks  
4 (2–6) (ns) 
(units not stated)  
Baseline 
5 (0–7) 
4wks 
5 (0–8) 
8wks  
3 (0–6) 
[94] Grape juice 300 ml juice, 
1600 
mg/day 
Not included Adult 
triathletes 
n=10 
34y 
100% M 
Single arm 3 weeks  Nailfold 
videocapillaroscopy. 
Functional capillary 
density  
(n/mm2) 
Baseline vs 3wks  
10.7 ± 2.3 vs 14.9 ± 2.7 
(p<0.05) 
N/A 
[95] Red wine 660 ml wine, 
approx. 220 
mg (acute) 
and 660 
mg/day (3 
weeks) 
None H 
n=18 
22y 
0% M 
 
Single arm Acute (1h) &  
3 weeks  
Forearm blood 
flow 
ACh, SNP 
(ml/min/100 ml) 
Baseline vs 1h resting 
FBF  
3.3±0.4 vs 5.6±0.7  
(p< 0.01) 
3 wks change from 
baseline  
ACh response: 2.6±1.3 
(p=0.06)  
SNP response: 1.9±0.6 
(p<0.01)  
N/A 
[97] Red vine leaf, 
AS 195 
360 mg Included, not 
defined 
CVI patients 
n=71 
67y 
23% M 
R, DB, C 6 weeks  Skin of ankle, LDF (AU; change from 
baseline)  
+241.8±18.7 (p<0.0001) 
(AU)  
-41.0±18.7  
1 CVI, chronic venous insufficiency; H, healthy; M, males; S, smokers; 2 C, crossover trial; DB, double blind; P, parallel arms; R, randomised; 3 ACh, acetylcholine; LDF, laser Doppler flowmetry; SNP, 
sodium nitroprusside; 4 ns, non-significant; AU, arbitrary units. 
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Table 5. Olive Oil.  
Author  Intervention 
Product 
Polyphenol 
Dose 
Control Population1 Study Design2 Study 
Duration  
Microcirculation 
Target3 
Outcome Measures4 
Active Control 
[101] PP-rich olive 
oil 
~30 mg/day PP-free olive oil EBP, S1H 
 
n=24 
26y (24-27) 
0% M 
DB, R, C 2 months  
(4 week 
washout) 
Forearm IRH  (PU) 
Baseline: 1084±266 
Change from baseline: 
+345±386 
(p<0.001 vs. Control)  
 
(PU)  
Baseline: 1084±266 
Change from baseline:  
+36±367 
 
 
[100] Phenol-rich 
olive oil (400 
ppm) 
400 ppm Low phenol olive 
oil (80 ppm) 
HC 
 
n=21 
59y (53-68) 
23.8% M 
R, S, C Acute 
(0h, 2h, 4h) 
Skin: palmar surface 
of second finger of 
dominant hand. IRH. 
(% increase in IRH AU) 
0h: 199±30 (ns)   
2h: 361±60 (p<0.018 vs 
Control)  
4h: 353±59 (0<0.039 vs 
Control)  
(% increase in IRH AU)  
0h: 253±37  
2h: 237±34  
4h: 260±37  
1 EBP, elevated normal blood pressure; HC, hypercholesterolaemic; M, males; S1H, stage 1 essential hypertension; 2 C, crossover trial; DB, double blind; R, randomised; S, sequential; 3 IRH, ischaemic 
reactive hyperaemia; 4 AU, arbitrary units; ns, non-significant; PU, perfusion units.  
 
  
Table 6: Pine Bark.  
Author Intervention 
Product 
Polyphenol 
Dose 
Control Population1 Study Design2 Study 
Duration  
Microcirculation 
Target3 
Outcome Measures4 
Active Control 
[108] Pycnogenol 
oral capsules 
150 mg/day No placebo 
given 
BH, HL, HG 
 
n=93 
Active n=49 
Control n=43 
 
45y 
51% M 
Pilot registry 
study 
12 weeks Skin, finger. 
LDF, SGP, RH 
Week 12 
LDF (% increase in 
baseline flux) 24.7±4.2* 
SGP (% increase in 
baseline volume flow) 
21.3±3.2* 
(*p<0.05 vs Control)  
Week 12 
LDF (% increase in baseline 
flux) 13.5±3.0 
SGP (% increase in baseline 
volume flow) 15.8±3.1 
 
[112] Pycnogenol 
oral capsules 
150 mg/day No placebo 
given 
Meniere’s 
disease, 
moderate 
tinnitus >2 wks 
n=107 
Active n=55 
Control n=52 
46y 
50% M 
Self-selection 
of group 
6 months  Cochlea. Doppler 
flow velocity of 
cochlear artery  
6 months (cm/s)  
Most affected ear:  
Systolic 21.2±1.1* 
Diastolic 14.1±1.2* 
Less affected ear:  
Systolic 23.4±1.0* 
Diastolic 16.3±1.0* 
(*p<0.05 vs Control)  
6 months (cm/s)  
Most affected ear:  
Systolic 16.1±2.2    
Diastolic 7.9±1.2   
Less affected ear:  
Systolic 21.3±1.1  
Diastolic 11.5±1.4  
[103] Pycnogenol 
oral capsules 
150 mg/day 
(P) or 
Compression 
stockings only 
(S) 
Severe CVI 
 
n=98 
R, P 8 weeks  Skin, ankle. LDF, 
capillary filtration as 
the rate of ankle 
Week 8  
LDF (RF):  
P: 1.6±0.8*; P+S: 1.3±0.6^ 
Week 8  
LDF (RF):  
2.4±0.9  
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150mg/d + 
compression 
stockings 
(P+S) 
 
P: n=33 
P+S n=34 
S n=31 
 
48y 
54% M 
swelling via SGP, 
transcutaneous pO2 
& pCO2 
SGP (mL/min/100mL 
tissue): P: 1.5±0.6*; P+S: 
1.3±0.6^ 
pO2 (mmHg):  
P: 50.1±4.2*; P+S: 
51.1±5.1^ 
(*p<0.05 vs Control) 
(^p<0.05 difference vs 
both other groups)  
 
SGP (mL/min/100mL 
tissue): 2.0±0.8 
 
pO2 (mmHg):  
46.1±4.2  
 
[114] Pycnogenol 
oral capsules 
150 mg/day Placebo Type 2 DM 
(>4y), EDR 
(moderate) 
n=46 
Active n=24 
Control n=22 
52y 
63% M 
R, DB, P 3 months  Retina. Laser 
Doppler flow velocity 
of central retinal 
artery 
(mild/moderate 
retinal oedema) 
3 months (cm/s)  
Retinal oedema 
Mild: 48±4* 
Moderate: 44±3* 
(*p<0.05 vs Control)  
3 months (cm/s)  
Retinal oedema  
Mild: 36±3 
Moderate:36±3*^ 
 
 
[102]  Pycnogenol 
oral capsules 
180 mg/dayy Placebo H 
 
n=16 
22y 
100% M 
R, DB, P 2 weeks  Skin, forearm. SGP, 
ACh, SNP 
(mL/min/100mL tissue) 
Baseline vs 2 weeks  
ACh 15µg/min  
12.72±4.90 vs 
18.68±3.97* 
SNP 1.5µg/min 
16.33±4.72 vs 15.97±4.36 
(*p<0.05 vs Control)  
(mL/min/100mL tissue) 
Baseline vs 2 weeks  
ACh 15µg/min  
15.29±7.47 vs 17.04±9.22 
(ns)  
SNP 1.5µg/min  
15.97±4.36 vs 17.66±4.84  
[105] Pycnogenol 
oral capsules 
150 mg/day No treatment 
group 
Severe CVI 
 
n=39 (21/18) 
53y 
52% M 
P 8 weeks  Skin, ankle. LDF, 
capillary filtration as 
the rate of ankle 
swelling via SGP 
 
Week 8 
LDF (RF): 1.93*  
SGP (mL/min/100mL 
tissue): 1.68* 
(*p<0.05 vs Control)  
Week 8  
LDF (RF): 3.00  
SGP (mL/min/100mL 
tissue): 2.15  
 
 
[106]  Pycnogenol 
oral capsules 
150 mg/day Placebo 
capsules 
150mg/d 
Severe diabetic 
microangiopathy 
 
n=60 
59y (55-68) 
60% M 
P 4 weeks  Skin, dorsum of foot; 
LDF, capillary 
filtration as the rate 
of ankle swelling via 
SGP  
 
Week 4 
LDF (RF): 2.20±0.30* 
SGP (mL/min/100mL 
tissue): 1.86±0.12* 
*p<0.05 vs Control  
Week 4  
LDF (RF): 3.24±0.40  
SGP (mL/min/100mL 
tissue): 2.22±0.07  
 
 
[107] Pycnogenol 
oral capsules 
 
 
 
150 mg/day 
(LD) or 300 
mg/day (HD) 
1000 
mg/day 
- CVI, venous 
hypertension, 
ankle oedema 
P150 n=24, 53y, 
58% M 
P300 n=20, 48y, 
60% M 
P 8 weeks  Ankle. LDF, capillary 
filtration as the rate 
of ankle swelling via 
SGP, pO2 & pCO2 
Baseline vs week 8 
LDF (RF):  
LD: 3.21±0.10 vs 
1.90±0.08*  
HD 3.40±0.10 vs 
2.10±0.01* 
SGP (mL/min/100mL 
tissue):  
LD: 2.38±0.20 vs. 
1.58±0.11*  
N/A 
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HD: 2.43±0.21 vs. 
1.70±0.10*  
pO2 (mmHg):  
LD: 46±5 vs 54±3*  
HD: 43±3 vs 49±3*  
pCO2 (mmHg):  
LD 32±2 vs. 27±3*  
HD 32±2 vs 27±1*  
(*p<0.05 baseline vs week 
8) 
[109] Pycnogenol 
oral capsules 
 
 
 
Pycnogenol 
oral capsules 
+ topical 
application of 
powder 
150 mg (50 
mg x 3 per 
day) 
 
 
150 mg/day 
+ 100 mg 
topically 
Control – no 
medical 
treatment 
Diabetic, severe 
microangiopathy 
n=22, 54y 
50% M 
Oral n=6, 54y, 
38% M 
Oral/t n=8, 54y, 
38% M 
Control n=8, 
52y, 50% M 
P 6 weeks  Skin, lower limb. 
LDF, 
transcutaneous PO2 
& PCO2 
Pycnogenol week 6 
PO2 (mmHg): 55±4 
PCO2 (mmHg): 29±2  
LDF (PU): 2.1±1.0  
Pycnogenol oral + topical 
week 6  
PO2 (mmHg): 58±3* 
PCO2 (mmHg): 27±3  
LDF (PU): 2.0±0.7  
(*p<0.05 with other 
groups)   
Week 6  
PO2 (mmHg): 48±3 
PCO2 (mmHg): 30±3 (ns) 
[110] Pycnogenol 
oral capsules 
150 mg (50 
mg x 3 per 
day) 
Placebo, 
equivalent dose 
Essential 
hypertension, 
distal oedema, 
on ACE 
inhibitors or 
Nifedipine 
n=53, 48y 
55% M 
P 8 weeks  Foot. Volumetric 
capillary filtration via 
SGP 
(mL/min per 100 
cm3)  
 
Week 8  
(mL/min/100cm3 tissue) 
ACE: 1.56±0.23  
Nifedipine: 1.61±0.20  
(ns vs Control)   
Week 8  
(mL/min/100cm3 tissue) 
ACE: 2.44±0.30  
Nifedipine: 2.48±0.30  
 
  
 
[111] Pycnogenol 
oral capsules 
 
 
Pycnogenol 
oral + topical  
150 mg (50 
mg x 3 per 
day) 
 
150 mg/day 
+ 100 mg 
topically 
every 2 days 
Control Severe CVI 
AVP >55mgHg 
n=16, 57y 
50% M 
P 6 weeks  Transcutaneous PO2 
& PCO2  
 
Pycnogenol week 6  
PO2 (mmHg): 55±4* 
PCO2 (mmHg): 29±2* 
Pycnogenol oral + topical  
PO2 (mmHg): 58±3* 
PCO2 (mmHg): 27±3* 
(ns vs Control)  
Week 6  
PO2 (mmHg): 48±1 
PCO2 (mmHg): 29±3 
 
[113]  Pycnogenol 150 mg/day 
 
Placebo Vascular retinal 
disorders 
n=40, 56y 
40% M 
Active n=30, 
60y, 40% M 
Control n=10, 
53y, 40% M 
R, DB, P 2 months  Retina. 
Fluoroangiography, 
electroretinogram 
(ERG) 
Fluoroangiography:  
Right: 1.30±0.18 
Left: 1.37±0.18 
 
ERG right: 0.73±0.14 
ERG left: 0.57±0.12 
 
(ns vs. Control)   
Fluoroangiography:  
Right: 1.30±0.21 
Left: 1.40±0.22 
 
ERG right: 0.70±0.26  
ERG left: 1.00±0.29 
 
1 ACE, angiotensin-converting-enzyme inhibitor; BH, borderline hypertensive; CVI, chronic venous insufficiency; DM, diabetes mellitus; EDR, early diabetic retinopathy; H, healthy; HG, hyperglycemic; HL, 
hyperlipidemic; M, males; 2 DB, double blind; P, parallel arms; R, randomised; 3 ACh, acetylcholine; LDF, laser Doppler flowmetry; pCO2, partial pressure of carbon dioxide; pO2, partial pressure of oxygen, 
RH, reactive hyperaemia; SGP, strain gauge plethysmography; SNP, sodium nitroprusside; 4 ns, not significant; RAS, rate of ankle swelling; RF, resting flux.  
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Table 7: Pure Polyphenol Compounds. 
Author  Product Polyphenol 
Dose 
Control Population1 Study 
Design2 
Study 
Duration  
Microcirculation 
Target3 
Outcome Measures4 
Active Control  
[117] Resveratrol 500 mg 
trans-
resveratrol 
 
Methyl-
cellulose 
H 
n=39 
20.5y 
18% M 
R, DB, P Acute (38 min) 
& 4 weeks  
Change in CBF 
prefrontal cortex, 
NIRS  
Total-Hb (µM)  
Acute: 1.57±0.24*  
4 weeks: 1.04±0.32 (ns) 
(*p<0.01 vs Control)  
Total-Hb (µM)  
Acute: 0.80±0.29  
4 weeks: 0.79±0.30  
[117] Resveratrol 
and 
resveratrol + 
piperine 
250 mg 
trans-
resveratrol 
Inert placebo H 
n=23 
21y 
17% M 
R, DB, P Acute (38 min) Change in CBF 
prefrontal cortex, 
NIRS 
Total-Hb (µM)  
-1.58±0.54 (ns)  
  
Total-Hb (µM)  
-1.36±0.62  
  
[118] Resveratrol 
with physical 
activity (PA) 
250 mg 
trans-
resveratrol 
Placebo, not 
specified 
H, physically 
inactive 
n=43 
65y 
100% M 
R, DB, P 8 weeks  Skeletal muscle 
capillary-to-fiber ratio  
Baseline vs week 8  
1.6±0.1 vs 1.7±0.1  
(ns) 
Baseline vs week 8  
1.5±0.2 vs 1.8±s0.1  
(p<0.005) 
[116] Resveratrol 250 mg and 
500 mg 
trans-
resveratrol 
Inert placebo H R, DB, CO Acute (45 min) Change in CBF 
prefrontal cortex, 
NIRS 
Total-Hb (µM)  
250 mg: 1.09±0.81 (ns)  
500 mg: 1.06±0.81 (ns) 
 
Total-Hb (µM) 
0.77±0.47  
 
 
[120] Hesperetin 100 ml water 
with water-
dispersible 
hesperetin 17 
and 170 mg 
Water H, cold 
sensitivity 
n=10 
18-22y 
0% M 
R, DB, CO Acute Annular finger of the 
left hand, laser-
Doppler 
(ml/min/100g)  
17 mg: -6.9±7.1* 
170 mg: -5.9±7.7^ 
(*p<0.0001 vs Control) 
(^p<0.0001 vs 17 mg) 
(ml/min/100g)  
-35.7±8.7  
[119] EGCG 135 and 
270mg 
Inert placebo H 
n=27 
22y 
41% M 
R, DB, CO Acute (45 min) Change in CBF 
prefrontal cortex, 
NIRS 
Total-Hb (µM)  
135 mg: -0.82±0.33 (ns)  
270 mg: -0.03±0.38 (ns)  
 
Total-Hb (µM)  
-0.13±0.40 
 
1 H, healthy adults; M, males; 2 C, crossover trial; DB, double blind; P, parallel arms; R, randomised; 3 CBF, cerebral blood flow; NIRS, near-infrared spectroscopy; 4 Hb, haemoglobin; ns, not-significant.  
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Table 8: Soy.  
Author  Product Polyphenol 
Dose 
Control Population1 Study 
Design2 
Study 
Duration  
Microcirculation 
Target3 
Outcome Measures4 
Active Control 
[140] Soy hypocotyl 
isoflavones 
(>95% 
glycosides) 
2 tablets daily 
(80 mg) 
(40.51 mg 
aglycone/tablet) 
Placebo (<1 mg 
aglycone/tablet) 
PM, EBP 
n=24 (12+12) 
55.6y 
(40-60y) 
0% M 
R, DB, P 6 weeks  FBF; SGP/ PRH  Week 6 (mL/min/100g 
tissue) 
FBF: 1.55±0.70 (ns) 
PRH: 17.0±8.1 (ns)  
 
Week 6 (mL/min/100g 
tissue) 
FBF: 1.92±0.55 
PRH: 22.3±8.0 
[122] Soy 
phytoestrogens 
(capsules: 
genistin & 
daidzin) 
55mg daily 
 
 
Placebo 
capsules 
H, PM 
n=22 
58.5y 
0% M 
R, DB, C 
(6 week 
washout) 
6 weeks 
 
Skin: LDV, 
ischaemia  
6 weeks (AUC)  
15537.6±13681.1 (ns)  
AUC response 
20924.0±10617.4 (ns)  
AUC ratio 2.5±2.4 (ns)  
6 weeks (AUC)  
13250.4±13523.4  
AUC response 
17490.1±11492.5  
AUC ratio 2.5±2.4 
[123] Soy isoflavone 
tablet 
80 mg daily (45 
mg Genistein) 
Placebo tablet H, PM, peri-
menopausal 
n=21 
54y 
0% M 
R, C 5-10 weeks  Skin; forearm VOP, 
ACh, SNP, 
ischaemia  
 
Basal flow 
(mL/min/100mL): 
3.75±1.42 
(% change) 
ACh37μg/min: 86.6±4.4 
(ns)  
SNP16μg/min: 68.9±12.6 
(ns)  
Ischaemia 87.6±5.1 (ns)  
Basal flow  
(mL/min/100mL):  
3.31±1.35 
(% change) 
ACh37μg/min: 84.8±7.3  
SNP16μg/min: 69.5±9.2  
Ischaemia 87.3±4.6 
1 EBP, elevated normal blood pressure; H, healthy; M, males; PM, post-menopausal; 2 C, crossover trial; DB, double blind; P, parallel arms; R, randomised; 3 ACh, acetylcholine; FBF, forearm blood 
flow; LDV, laser Doppler velocimetry; PRH, peak reactive hyperaemia; SGP, strain-gauge plethysmography; SNP, sodium nitroprusside; VOP, venous occlusion plethysmography; 4 AUC, area under the 
curve; ns, non-significant.  
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Table 9: Tea.  
Author  Intervention 
Product 
Polyphenol 
Dose 
Control Population1 Study 
Design2 
Study 
Duration  
Microcirculation 
Target3 
Outcome Measures4 
Active Control 
[124] Flavonoid-rich 
black tea 
beverage 
 
100 ml drink 
(228.1 mg 
polyphenols) 
 
100ml water O, IR 
n=16, 61y 
100% M 
R, SB, C 3 hours 
(2-7 day 
washout)  
Forearm NIRS & 
VOP, leg VOP 
 
Vascular resistance; 
LSMeans over all time 
points 
VOP arm 
(mmHg/min/100ml/ml): 
48 (ns) 
VOP leg 
(mmHg/min/100ml/ml): 
38 (p=0.04) 
NIRS arm (AU): 84* 
(p<0.002 vs Control) 
Vascular resistance; 
LSMeans over all time 
points 
VOP arm 
(mmHg/min/100ml/ml):  
50  
VOP leg 
(mmHg/min/100ml/ml):  
40  
NIRS arm (AU): 112  
[126] Green tea 
extract 
836 mg green 
tea catechins 
- H, NS, OW 
n=20, 70% M 
Homozygous 
COMT genotype 
(AA: n=10; GG: 
n=10) 
Pilot Acute 
(0-480 min) 
Skin: LDI 
iontophoresis, ACh, 
SNP 
 
 
Change from baseline 
(AUC) for combined 
genotypes  
ACh: -1547±723 (ns) 
SNP: -1728±895 (ns) 
Change from baseline 
(AUC) for combined 
genotypes  
ACh: -1024±413 (ns) 
SNP: -1344±748 (ns) 
[125] Green tea 
beverage 
1402 mg 
catechins/day 
Constituent 
matched 
beverage 
H, normal type II 
skin 
 
n=60 (30 per 
group) 
40-65y, 0% M 
R, DB, P 12 weeks 
(measures 0, 
6, 12 weeks)  
Skin (1mm depth): 
LDF & oxygen 
saturation via O2C 
system 
0, 6, 12 weeks 
LDF (AU): 9.5±4.3, 
13.3±6.0, 12.3±5.2 
0-6 wks % change: +40* 
0-12 wks % change: 
+29* 
O2 saturation (%)  
29.7±17.5, 38.2±21.1, 
39.7±20.2 
0-6wks % change: +29* 
0-12wks % change: +34* 
(*p<0.05 vs Control) 
0, 6, 12 weeks  
LDF (AU): 11.4±4.6, 
10.6±4.5,11.5±4.3 
0-6 wks % change: -7.0 
0-12 wks %change: +0.9 
 
O2 saturation (%)  
25.2±20.0, 23.2±16.7, 
24.3±17.8 
0-6wks % change: -7.9 
0-12wks % change: -3.6 
Green tea 
extract 
Single dose (0.5, 
1.0, 2.0 g) 
- n=15 
0% M 
R, DB, P Acute 
(0-240 min) 
Skin (1mm depth): 
LDF, O2C system 
(AU)  
Baseline, peak, 2h  
0.5g: 5.0±2.8, 9.0±4.0, 
5.1±2.0  
1.0g: 6.0±2.8, 9.9±3.3, 
6.0±2.0  
2.0g: 4.9±1.1,10.9±4.6, 
6.1±2.2  
(ns) 
N/A 
[132] Green tea 
beverage – 
medium and 
high dose 
groups 
Medium dose: 
80 mg/day 
High dose: 580 
mg/day 
Catechin-free 
beverage  
(0 mg) 
H, S  
n=30, 35y,M: 
37y 
H: 35y, CF: 35y 
100% M 
R, P 1, 2 weeks 
+ acute (2h) 
Skin: forearm VOP, 
ACh, SNP 
 
(ml/min*100ml tissue) 
Acute 
Medium dose:  
ACh:12.62±1.21 
SNP: 8.86±0.39 
High dose:  
(ml/min*100ml tissue) 
Acute  
ACh: 11.74±1.16 
SNP: 11.74±1.16 
 
 
49 
 
ACh: 14.96±0.98* 
SNP: 9.96±0.08 
 
Days 7 and 14 
Medium dose: 
ACh: 12.00±1.43, 
13.43±1.14 
SNP: 8.64±0.60, 14 
9.14±0.50 
High dose: 
ACh: 15.54±0.95*, 
16.89±0.68* 
SNP: 10.32±0.49, 
10.22±0.49 
(*p<0.01 vs pre-
treatment)   
 
 
 
Days 7 and 14 
 
ACh: 11.88±1.01, 
12.02±1.31 
SNP: 9.23±0.31, 
8.92±0.73 
 
 
[127] Green tea 
extract gelatin 
capsules 
(384mg, 
containing 
119mg 
polyphenols) 
6 capsules/day 
(714 mg/day 
polyphenols) 
Caffeine 
matched 
gelatin 
capsules 
H 
n=33 (17/16), 
41y, 100% M 
DB, P 3 weeks  Skin: forearm LDI, 
ACh, SNP  
(AU)  
Baseline vs 3 weeks  
ACh: 3576±2060 vs 
3221 ± 1751 (ns)  
SNP: 4094 ± 2165 vs 
4399 ± 2428 (ns)  
(AU)  
Baseline vs 3 weeks  
ACh: 3016±1517 vs 
3216±1557 
SNP 4368±2161 vs 
4552±2318  
1 COMT, catechol-O-methyltransferase; H, healthy; IR, insulin resistant (>5.55mmol/l); M, males; NS, non-smokers; O, obese (BMI>30 kg/m2); OW, overweight (BMI 25-32kg/m2); S, smokers; 2 C, 
crossover trial; DB, double blind; P, parallel arms; R, randomised; SB, single blind; 3 ACh, acetylcholine; LDF, laser Doppler flowmetry; LDI, laser Doppler iontophoresis; NIRS, near infra-red 
spectroscopy; SNP, sodium nitroprusside; VOP, venous occlusion plethysmography; 4 AU, arbitrary units; AUC, area under the curve; LSMeans, least-squares means; ns, not significant.  
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Table 10: Summary of polyphenol sources and their acute and chronic effectiveness in improving microvascular function.  
 
Polyphenol Source 
Outcome 
Acute Chronic 
Berries Not effective  Effective (retinopathy) 
Cocoa Effective Effective 
Daflon Effective Effective  
Grape and wine Equivocal  Effective  
Olive oil Not effective Effective 
Pine bark  Unknown Effective  
Pure compounds Equivocal Equivocal 
Soy Unknown Not effective 
Tea Effective  Effective  
 
 
 
 
 
